NASDAQ:PTPI Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis $0.0059 0.00 (0.00%) As of 06/26/2026 01:47 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Petros Pharmaceuticals Stock (NASDAQ:PTPI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Petros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0058▼$0.007350-Day Range$0.0055▼$0.008152-Week Range$0.00▼$0.04Volume28,881 shsAverage Volume102,022 shsMarket Capitalization$183.84 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York. Read More Receive PTPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTPI Stock News HeadlinesFinancial Contrast: Petros Pharmaceuticals (NASDAQ:PTPI) versus MindWalk (NASDAQ:HYFT)June 25, 2026 | americanbankingnews.comPetros Pharmaceuticals (NASDAQ:PTPI) & Whitehawk Therapeutics (NASDAQ:WHWK) Head-To-Head SurveyJune 24, 2026 | americanbankingnews.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 29 at 1:00 AM | Porter & Company (Ad)Petros Pharmaceuticals Delays Annual 10-K FilingMarch 31, 2026 | tipranks.comPetros Pharmaceuticals grants significant RSUs to key leadersJanuary 3, 2026 | msn.comPetros Pharmaceuticals to be Delisted from NasdaqNovember 7, 2025 | msn.comPetros Pharmaceuticals Inc (PTPI) - Investing.comSeptember 6, 2025 | investing.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...June 26, 2025 | finanznachrichten.deSee More Headlines PTPI Stock Analysis - Frequently Asked Questions How have PTPI shares performed this year? Petros Pharmaceuticals' stock was trading at $0.0071 at the beginning of the year. Since then, PTPI stock has decreased by 16.9% and is now trading at $0.0059. How were Petros Pharmaceuticals' earnings last quarter? Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) posted its earnings results on Thursday, May, 15th. The company reported ($8.46) earnings per share (EPS) for the quarter. When did Petros Pharmaceuticals' stock split? Petros Pharmaceuticals shares reverse split on Thursday, May 1st 2025.The 1-25 reverse split was announced on Tuesday, April 29th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Petros Pharmaceuticals? Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Petros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings5/15/2025Today6/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTPI CIK1815903 Webwww.petrospharma.com Phone973-242-0005FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.16 million Net MarginsN/A Pretax Margin-117.50% Return on Equity-78.22% Return on Assets-23.50% Debt Debt-to-Equity Ratio1.58 Current Ratio0.85 Quick Ratio0.74 Sales & Book Value Annual Sales$5.11 million Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.00Miscellaneous Outstanding Shares31,160,000Free Float9,932,000Market Cap$183.84 thousand OptionableNot Optionable Beta1.86 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PTPI) was last updated on 6/29/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts